Neurologix, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and Central Nervous System. The company’s treatments are designed as alternatives to conventional surgical and pharmacological treatments. It focuses on gene therapy for treating Parkinson’s disease, a neurodegenerative disorder; and epilepsy, a group of diseases associated with recurrent seizures, which is caused by periodic episodes of repetitive, abnormal electrochemical disturbance in the central nervous system, beginning in the brain. The company also focuses on the treatment of other neurodegenerative and metabolic disorders, including Huntington’s disease, depression, and metabolic syndrome or genetically-based obesity. Neurologix, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.
